<DOC>
	<DOCNO>NCT00383994</DOCNO>
	<brief_summary>The goal clinical research study find give boost natural killer ( NK ) cell donor combine Rituxan ( rituximab ) , help control disease patient already receive allogeneic stem cell transplant . The safety treatment also study . Participants recurrent chronic lymphocytic leukemia ( CLL ) lymphoma non-myeloablative stem cell transplantation . Primary Objectives : 1.0 To determine safety Natural Killer ( NK ) cell Rituximab + rhu-Granulocyte-macrophage colony-stimulating factor ( GMCSF ) patient persistent recurrent B-cell lymphoid malignancy non-myeloablative stem cell transplantation . 2.0 To determine factor associate response .</brief_summary>
	<brief_title>Immunotherapy With NK Cell , Rituximab Rhu-GMCSF Non-Myeloablative Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description>Rituximab design attach lymphoma cell , cause die . GM-CSF NK cell may increase rituximab 's ability kill cell . Before start treatment study , call `` screening test . '' These test help doctor decide eligible take part study . You complete medical history record physical exam . Your blood ( 2 tablespoon ) collect routine test . A bone marrow aspirate perform . To collect bone marrow aspirate , area hip chest bone numb anesthetic small amount bone marrow withdrawn large needle . You computerized tomography ( CT ) scan well positron emission tomography ( PET ) gallium scan learn status disease . Women able child must negative blood urine pregnancy test . If find eligible take part study , receive treatment outpatient . You receive GM-CSF 3 time week 4 week vein , start day receive administration rituximab . You receive rituximab 4 8 hour vein , weekly 4 week . You also get boost NK cell donor receive original transplant . These cell infuse vein ( 30 60 minute ) 4th dose rituximab . If receive cell infusion somebody related , infusion may do later cell available schedule . The CliniMACS System medical device use separate type blood cell blood remove body leukapheresis . These separated cell process use treatment stem cell transplant . During treatment , examine need , blood sample ( 1 tablespoon twice week ) take routine test . You may need receive blood transfusion study blood cell count remain low . You may take study disease get bad intolerable side effect occur . You long-term , follow-up visit study . You see 4 6 week receive NK cell infusion ; every 3 month first year ; year . During visit , CT PET scan , bone marrow biopsy , blood drawn ( 4 teaspoon ) learn status disease . This investigational study . Rituximab GM-CSF FDA approve commercially available . NK cell authorize FDA use research . Up 40 participant take part study . All enrol University Texas ( UT ) MD Anderson Cancer Center .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Patients previous diagnosis CD20+ Bcell CLL nonHodgkin 's lymphoma fail standard conventional chemotherapy , persistent disease 3 month , progressive disease nonmyeloablative allogeneic transplantation . 2 . Donor willingness donate peripheral blood ( donor original transplant ) . 3 . Negative Beta HCG woman child bear potential define postmenopausal 12 month previous surgical sterilization . 1 . Pregnancy lactation 2 . HIV , HTLVI hepatitis . 3 . Active infection ( ) &gt; /= grade 3 . 4 . Severe active concomitant medical psychiatric illness . 5 . Concurrent active GVHD require tacrolimus</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>B-Cell Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>granulocyte-macrophage colony-stimulating factor</keyword>
	<keyword>Leukemia</keyword>
	<keyword>NK Cells</keyword>
	<keyword>Rituximab</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Non-myeloablative Allogeneic Stem Cell Transplantation</keyword>
	<keyword>Stem Cell Transplant</keyword>
</DOC>